Here, we found that SUCLA2 was significantly decreased in AD brain and blood cells, and correlated with Aβ, Tau and MMSE scores, suggesting that SUCLA2 may be closely related to the pathological development and cognitive impairment of AD, and it may be a potential diagnostic and therapeutic target. Here, MAPT is linked to Cognitive impairment.